Current opinion on optimal treatment for colorectal cancer

Price, T.J., Segelov, E., Burge, M., Haller, D.G., Ackland, S.P., Tebbutt, N.C., Karapetis, C.S., Pavlakis, N., Sobrero, A.F., Cunningham, D. and Shapiro, J.D. (2013) Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13 5: 597-611. doi:10.1586/era.13.37

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Price, T.J.
Segelov, E.
Burge, M.
Haller, D.G.
Ackland, S.P.
Tebbutt, N.C.
Karapetis, C.S.
Pavlakis, N.
Sobrero, A.F.
Cunningham, D.
Shapiro, J.D.
Title Current opinion on optimal treatment for colorectal cancer
Journal name Expert Review of Anticancer Therapy   Check publisher's open access policy
ISSN 1473-7140
1744-8328
Publication date 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1586/era.13.37
Open Access Status
Volume 13
Issue 5
Start page 597
End page 611
Total pages 15
Place of publication London, England, U.K.
Publisher Expert Reviews Ltd.
Collection year 2014
Language eng
Subject 2736 Pharmacology (medical)
2730 Oncology
Abstract The medical treatment of colorectal cancer (CRC) has evolved greatly in the last 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Advances in adjuvant therapy have been limited to the addition of oxaliplatin and the substitution of oral fluoropyrimidine (e.g., capecitabine) for intravenous 5-fluorouracil with no evidence for improved outcome with biological agents. Clinical benefit from the use of the targeted monoclonal antibodies, bevacizumab, cetuximab and panitumumab, in the treatment of metastatic CRC is now well established, but the optimal timing of their use requires careful consideration to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and EGF receptor-targeted biological agents (cetuximab and panitumumab) in the treatment of metastatic CRC. This article reviews the evidence in support of modern treatments for CRC and the decision-making behind the treatment choices, their benefits and toxicities.
Keyword biological
chemotherapy
colorectal cancer
consensus
KRAS
VEGF
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 15 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 24 Feb 2014, 08:31:03 EST by Matthew Lamb on behalf of School of Medicine